Opportunities Amid Crisis: Junshi, Allist Look To Expand Pipelines Through Alliances, M&A

Against the prevailing headwinds in the biotech sector, two Chinese firms are bucking the trend of pipeline reorganization by eyeing the potential acquisition of assets from external partners to expand into more modalities and therapeutic areas.